Pharmacogenetic considerations in the treatment of cancer pain

Cancer Pain: Assessment and Management, Second Edition

Volumn , Issue , 2009, Pages 180-194

  Inturrisi, Charles E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927068443     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511642357.011     Document Type: Chapter

References (128)

1. Kim H, Dionne RA. Genetics, pain, and analgesia. Pain Clinical Updates XII:1-4, 2005.
2. Cepeda MS, Farrar JT, Roa JH, et al. Ethnicity influences morphine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 70:351-61, 2001.
3. Zhou HH, Sheller JR, Nu HE, et al. Ethnic differences in response to morphine. Clin Pharmacol Ther 54:507-13, 1993.
4. Colson NJ, Fernandez F, Lea RA, Griffiths LR. The search for migraine genes: an overview of current literature. Cell Mol Life Sci 64:331-44, 2007.
5. Ablin JN, Cohen H, Buskila D. Mechanism of disease: genetics of fibromyalgia. Nat Clin Pract Rheumatol 2:671-8, 2006.
6. Klepstad P. Genetic variability and opioid efficacy. Curr Anaesth Crit Care 18:149-56, 2007.
7. Lotsch J, Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. Pain 121:1-5, 2006.
8. McQuay HJ, Carroll D, Faura CC, et al. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 48:236-44, 1990.
9. Klepstad P, Kaasa S, Skauge M, Borchgrevink PC: Pain intensity and side effects during titration of morphine to cancer patients using a scheduled fixed dose escalation. Acta Anaes- thesiol Scand 44:656-64, 2000.
10. Aubrun F, Langeron O, Quesnel C, et al. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous titration. Anesthesiology 98:1415-25, 2003.
11. Aubrun F, Monsel S, Langeron O, et al. Postoperative titration of intravenous morphine in the elderly patient. Anesthesiology 96:17-23, 2002.
12. Evans WE, McLeod HL. Pharmacogenetics - drug disposition, drug targets, and side effects. N Engl J Med 348:538-49, 2003.
13. Reyes-Gibby CC, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130:25-30, 2007.
14. Guttmacher AE, Collins FS. Genomic medicine - a primer. N Engl J Med 347:1512-20, 2002.
15. Kimchi-Sarfaty C, Oh JM, Kim I-W, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-8, 2007.
16. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299:1240-3, 2003.
17. Rakvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116:73-8, 2005.
18. Nackley AG, Shabalina SA, Tchivileva IE, et al. Human catechol-O-methyltransferase haplotyopes modulate protein expression by altering mRNA secondary structure. Science 314:1930-3, 2006.
19. Ross JR, Riley J, Taegetmeyer AB, et al. Genetic variation and response to morphine in cancer patients: catechol-O- methyltransferase (COMT) and multi-drug resistance (MDR- 1) gene polymorphism are associated with central side effects. Cancer 112:1390-403, 2008.
20. Sherry ST, Ward M, Sirotkin K. dbSNP - database for single nucleotide polymorphism and other class of minor genetic variation. Genome Res 9:677-9, 1999.
21. den Dunnen JT, Antonerakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations. Hum Mutat 15:7-12, 2000.
22. Kvam TM, Baar C, Rakvag TT, et al. Genetic analysis of the murine mu opioid receptor: increased complexity of Oprm gene splicing. J Mol Med 82:250-5, 2004.
23. Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 22:67-70, 2001.
24. Rossi GC, Leventhal L, Pan YX, et al. Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6-glucuronide antinociception. J Pharmacol Exp Ther 281:109-14, 1997.
25. Abbadie C, Pan YX, Pasternak GW. Differential distribution in rat brain of mu opioid receptor carboxy terminal splice variants MOR-1C-like and MOR-1-like immunoreactivity: evidence for region-specific processing. J Comp Neurol 419:244-56, 2000.
26. Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage 29: S2-9, 2005.
27. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10:378-84, 1995.
28. Bolan EA, Tallrida RJ, Pasternak GW. Synergy between μ opioid ligands: evidence for functional interactions among μ opioid receptor subtypes. J Pharmacol Exp Ther 303:557-62, 2002.
29. Pan YX, Xu J, Mahurter L, et al. Identification and characterization of two human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem Biophys Res Commun 301:1057-61, 2003.
30. Larivere WR, Wiolson SG, Laughlin TM, et al. Heritability of nociception. III. Genetic relationship among commonly used assays of nociception and hypersensitivity. Pain 97:75-86, 2002.
31. Mogil JS. Pain genetics: pre- and post-genomic findings. Glenview, IL: International Association for the Study of Pain, 2000.
32. Nielsen CS, Stubhaug A, Price DD, et al. Individual differences in pain sensitivity: Genetic and environmental contributions. Pain 136:21-9, 2008.
33. Edwards CL, Fillingim RB, Keefe F. Race, ethnicity and pain. Pain 94:133-7, 2001.
34. Lötsch J, Stuck B, Hummel T. The human μ-opioid receptor gene polymorphism 118A > G decreases cortical activation in response to specific nociceptive stimuli. Behav Neurosci 120:1218-24, 2006.
35. Fillingim RB, Kaplan L, Staud R, et al. The A118G single nucleotide polymorphism of the ^-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 6:159-67, 2005.
36. Nacley AG, Tan KS, Fecho K, et al. Catechol-O- methyltransferase inhibition increases pain sensitivity through activation of both p2- and p3-adrenergic receptors. Pain 128:199-208, 2007.
37. Poulsen L, Riishede L, Brosen K, et al. Codeine in postoperative pain. Study of the influence of sparteine phenotype and serum concentration of morphine and morphine-6- glucuronide. Eur J Clin Pharmacol 54:451-4, 1998.
38. Osborne R, Joel S, Trew D, Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet 1:828, 1988.
39. Portenoy RK, Thaler HT, Inturrisi CE, et al. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther 51:422-31, 1992.
40. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-95, 1997.
41. Sindrup SH, Brøsen K. The pharmacogenetics of codeine hypoanalgesia. Pharmacogenetics 5:335-46, 1995.
42. Poulsen L, Br0sen K, Arendt-Nielsen L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 51:289-95, 1996.
43. Williams DG, Patel A, Howard RF. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth 89:839-45, 2002.
44. Kirkwood LC, Nation RL, Somogyi A. Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. Br J Clin Pharmacol 44:549-55, 1997.
45. Hutchinson MR, Menelaou A, Foster DJ, et al. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver enzymes. Br J Clin Pharmacol 57:287-97, 2004.
46. Lalovic B, Phillps B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A4 to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32:447-54, 2004.
47. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64:603-11, 1998.
48. Otton SV, Schadel M, Cheung SW, et al. CYP2D6 genotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993:463-72, 1993.
49. Stamer UM, Lehnen K, Hithker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105:231-8, 2003.
50. Poulsen L, Arendt-Nielsen L, Brøsen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 60:636-44, 1996.
51. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and responses to treatment. Clin Pharmacol Ther 80:668-70, 2006.
52. Eap CB, Broly F, Mino A, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psy- chopharmacol 21:229-34, 2001.
53. Coller JK, Joergensen C, Foster DJ, et al.: Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic- methadone. Int J Clin Pharmacol Ther 45:410-17, 2007.
54. Crettol S, Deglon JJ, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593-604, 2005.
55. Wang JS, De Vane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (R)-methadone in vivo. Drug Metab Dispos 31:742-7, 2003.
56. Lotsch J, Skarke C, Wieting J, et al. Modulation of the central nervous effect of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 79:72-89, 2006.
57. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1-4, 1997.
58. Holthe M, Rakvag TN, Klepstad P, et al. Sequence variation in the UDP-glucurosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 3:17-26, 2003.
59. Sawyer MB, Innoceti F, Das S, et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 73:566-74, 2003.
60. Dugay Y, Baar C, Skorpen F, Guillemette C. A novel functional polymorphism in the uridine diphosphate- glucuronyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 75:223-33, 2004.
61. Toide K, Takahashi Y, Yamazaki H, et al. Hepatocyte nuclear factor-1a is a causal factor responsible for the interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers. Drug Metab Dispos 30:613-15, 2002.
62. Coulbault L, Beaussier M, Verstuyft C, et al. Environmental and genetic factors associated with morphine responses in the postoperative period. Clin Pharmacol Ther 79:316-24, 2006.
63. Ross JR, Ruttler D, Welsh K, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 5:324-36, 2005.
64. Holthe M, Klepstad P, Zahlsen K, et al. Morphine glucuronide- to-plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 58:353-6, 2002.
65. Skarke C, Scmidt H, Geisslinger G, et al. Pharmacokinetics are not altered in subjects with Gilbert’s syndrome. Br J Clin Pharmacol 56:228-31, 2003.
66. Klepstad P, Borchgrevink PC, Dale O, et al. Relations between serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide and clinical observations: a prospective survey in 300 cancer patients. Acta Anaesthesiol Scand 47:725-31, 2003.
67. Hoehe MR, Kopke K, Wendel B, et al. Sequence variability and candidate gene analysis in complex disease: association of p. opioid receptor gene variation with substance dependence. Hum Mol Genet 9:2895-908, 2000.
68. Wang D, Quillan JM, Winans K, et al. Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem 276:34624-30, 2001.
69. Befort K, Filiol D, Decalliot FM, et al. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276:3130-7, 2001.
70. Zhang Y, Wang D, Johnson AD, et al. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280:32618-24, 2005.
71. Skarke C, Darimont J, Schmidt H, et al. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 73:107-21, 2003.
72. Lötsch J, Skarke C, Grosch S, et al. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12:3-9, 2002.
73. Romberg R, Olufsen E, Sarton E, et al. Pharmacokinetic- pharmacodynamic modeling of morphine-6-glucuronide analgesia in healthy volunteers. Anesthesiology 100:120-33, 2004.
74. Romberg R, Olufsen E, Bijl H, et al.G does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102:522-30, 2005.
75. Oertel BG, Schmidt R, Schneider A, et al.G depletes alfentanil- induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 16:62536, 2006.
76. Klepstad P, Rakvag TN, Kaasa S, et al.G polymorphism in the human p-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48:1232-9, 2004.
77. Campa D, Gioia A, Tomei A, et al. Association of ACCB1/MDR1 and OPRM1 gene polymorphism with morphine pain relief. Clin Pharm Ther 83:559-66, 2008.
78. Caraco Y, Maroz Y, Davidson E. Variability in alfentanil analgesia may be attributed to polymorphism in the p-opioid receptor. Clin Pharmacol Ther 69: P63, 2001.
79. Chou WY, Yang LC, Lu HF, et al. Association of mu opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 50:787-92, 2006.
80. Chou WY, Wang CH, Liu P-H, et al. Human opioid receptor A118G polymorphisms affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 105:334-7, 2006.
81. Sia AT, Lim Y, Lim ECP, et al. A118G single nucleotide polymorphism of human p-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 109:520-6, 2008.
82. Janicki PK, Shculer G, Francis D, et al. A genetic association study of the functional A118G polymorphism of the human p-opioid receptor gene in patients with acute and chronic pain. Anesth Analg 103:1011-17, 2006.
83. Beyer A, Koch T, Schroder H, et al. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89:553-60, 2004.
84. Landau R, Kern C, Columb MO, et al. Genetic variability of the μ-opioid receptor influences intrathecal fentanyl variability in labouring women. Pain 139:5-14, 2008.
85. Bond C, La Forge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95:9608-13, 1998.
86. Bayerer B, Stamer U, Hoeft A, Stuber F. Genomic variations and transcriptional regulation of the human mu-opioid receptor gene. Eur J Pain 11:421-7, 2007.
87. Law PY, Yang JW, Guo X, Loh HH. In vivo activation of a mutant μ-opioid receptor by antagonist: future direction for opiate pain treatment paradigm that lacks undesirable side effects. Proc Natl Acad Sci U S A 100:2117-21, 2003.
88. Ross FB, Smith MB. The intrinsic antinociceptive effects of oxycodone appear to be k-opioid receptor mediated. Pain 73:151-7, 1997.
89. Kim H, Neubert JK, Miguel AS, et al. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 109:488-96, 2004.
90. Somogyi A, Barrat DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 81:429-44, 2007.
91. Wandel C, Kim R, Wood M, Wood A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96:913-20, 2002.
92. Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P- glycoprotein. Anesthesiology 92:1392-9, 2000.
93. Daganais C, Graff CL, Pollack GM. Variable modulation of brain uptake by P-glycoprotein in mice. Biochem Pharmacol 15:269-76, 2004.
94. Meineke I, Freudenthaler S, Hofmann U, et al. Pharmacokinetic modeling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol 54:592-603, 2002.
95. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P- glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473-8, 2000.
96. Klepstad P, Dale O, Skorpen F, et al. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 49:902-8, 2005.
97. Skarke C, Jarrar M, Erb K, et al. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 74:303-11, 2003.
98. Coller JK, Barrat DT, Dahlen K, et al. ABCB genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 80:682-90, 2006.
99. Park HJ, Shinn HK, Ryu SH, et al. Genetic polymorphisms in the ABCB gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 81:539-46, 2007.
100. Ganapathy V, Miyauchi S. Transport systems for opioid peptides in mammalian tissue. AAPS J 29: E852-6, 2005.
101. Niemi G, Breivik H. The minimally effective concentration of adrenaline in a low-concentration thoracic epidural analgesic infusion of bupivacaine, fentanyl and adrenaline after major surgery. Acta Anaesthesiol Scand 47:439-50, 2003.
102. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34:4202-10, 1995.
103. Rakvag TT, Ross JR, Sato H, et al. Genetic variation in the Catechol-O-Methyltransferase (COMT) gene and morphine requirements in cancer pain patients. Mol Pain 4:64, 2008.
104. Xia Y, Wikberg JES, Chajlani V. Expression of melanocortin 1 receptor in periaqueductal gray matter. Neuroreport 6:219-36, 1995.
105. Mogil JS, Ritchie J, Smith SB, et al. Melanocortin-1 receptor gene variants affect pain and ^-opioid analgesia in mice and humans. J Med Genet 42:583-7, 2005.
106. Mogil JS, Wilson SG, Chesler EJ, et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci USA 100:486-772, 2003.
107. Wolf G, Gabay E, Tal M, et al. Genetic impairment of interleukin-1 signaling attenuates neuropathic pain, autonomy, and spontaneous ectopic neuronal activity, following nerve injury in mice. Pain 120:315-24, 2006.
108. Bessler H, Shavit Y, Mayburd E, et al. Postoperative pain, morphine consumption, and genetic polymorphism of IL- 1beta and IL-1 receptor antagonist. Neurosci Lett 404:154-8, 2006.
109. Bohn LM, Lefkowitz RJ, Gainetdinov RR, et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495-8, 1999.
110. Raehal KM, Walker JK, Bohn LM. Morphine side effects in β-arrestin 2 knockout mice. J Pharmacol Exp Ther 314:1195-201, 2005.
111. Bohn LM, Galnetdinov RR, Lin F-L, et al. μ-Opioid receptor desensitization by P-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720-3, 2000.
112. Krauss J, Borner C, Giannini E, et al. Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J Biol Chem 276:43901-8, 2001.
113. Meuser T, Giesecke T, Gabriel A, et al. Mu-opioid receptor mRNA regulation during morphine tolerance in the rat peripheral nervous system. Anesthesiology 97:1458-63, 2003.
114. Liang DY, Liao G, Wang J, et al. A genetic analysis of opioid- induced hyperanalgesia in mice. Anesthesiology 104:1054-62, 2006.
115. Diatchenko L, Anderson AD, Slade GD, et al. Three major haplotypes of the beta2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder. Am J Med Genet B Neuropsychatr Genet 141:449-62, 2006.
116. Liang DY, Liao G, Lighthall GK, et al. Genetic variants of the P-glycoprotein gene Abcb1b modulate opioid-induced hyperalgesia, tolerance and dependence. Pharmacogenet Genomics 16:825-35, 2006.
117. Mikus G, Trausch B, Rodewald C, et al. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Clin Pharmacol Ther 61:459-66, 1997.
118. Hasselstrom J, Yue OY, Sawe J. The effect of codeine on gastrointestinal transit in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol 53:145-8, 1997.
119. Eckhardt K, Li S, Ammon S, et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 76:27-33, 1998.
120. Wang G, Zhang H, He F, Fang X: Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 62:927-31, 2006.
121. Thirlwell MP, Sloan PA, Maroun JA, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled- release morphine tablets in cancer patients. Cancer 63:2275-83, 1989.
122. Collin E, Poulain P, Gauvain-Piquard A, et al. Is disease progression the major factor in morphine “tolerance” in cancer pain treatment? Pain 55:319-26, 1993.
123. Klepstad P, Borchgrevink PC, Dale O, et al. Routine drug monitoring of serum concentrations of morphine. Morphine-3- glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. Palliat Med 17:679-87, 2003.
124. Yun CH, Wood M, Wood A., Guengerich FP. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance. Anesthesiology 77:467-74, 1992.
125. Reilly SC, Cossins AR, Quinn JP, Sneddon LU. Discovering genes: the use of microarrays and laser capture microdissection in pain research. Brain Res Rev 46:225-33, 2004.
126. Max MB. Assessing pain candidate gene studies. Pain 109:13, 2004.
127. Belfer I, Wu T, Kingman A, et al. Candidate gene studies of human pain mechanism. Anesthesiology 100:1562-72, 2004.
128. Freely associating [editorial]. Nat Genet 22:1-2, 1999.